Acrivon is developing targeted therapies to improve the lives of patients. At the frontier of proteomics, Acrivon’s proprietary patient selection method is designed to profoundly alter precision oncology drug development and the treatment landscape of patients suffering from cancer. Powered by our AP3 platform, we match drug mechanisms to the biologic drivers of cancer in patients, uncovering drug sensitivity not achievable through genomics.
Accelerated precision oncology
Committed to delivering real therapeutic outcomes for patients
Aiming to address the world’s most common and pressing cancers, Acrivon’s technology and pipeline is built to improve patient outcomes.
This is possible due to our unique OncoSignature® patient selection test, which is designed to accurately match our drug candidates with patients whose tumors are predicted to be sensitive.
Our pipelineOur pipeline is initially focused on DNA Damage Response, cell cycle, and transcriptional regulators.
Our lead program, ACR-368 (also known as Prexasertib, in-licensed from Lilly), is a clinically-advanced, potent selective kinase inhibitor of the DNA Damage Response. Currently in phase 2 clinical development, ACR-368 has demonstrated deep, durable single agent anti-tumor clinical activity, including complete responses, in a proportion of patients and a generally favorable safety and tolerability profile across multiple high unmet need solid cancer types.
Our two preclinical, internally-developed pipeline programs target critical nodes involved in the DNA Damage Response and cell cycle regulation pathways.
Partnering with AcrivonImpactful therapeutics matched to the right patients
Our AP3 platform is designed to be broadly applicable and suitable for strategic co-development partnerships around predictive OncoSignature tests for drug candidates with potential for accelerated approval, or for marketed drugs based on increased overall response rates. We continually assess in-licensing and partnering opportunities with like-minded visionary companies.